Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

NCT00118157 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor Positive
Male Breast Carcinoma
Progesterone Receptor Positive
Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Lapatinib Ditosylate
DRUG: Tamoxifen Citrate

Sponsor

National Cancer Institute (NCI)